Medtronic & #039;s Value-Based Partnerships are Paying Off in Spades

Dublin, Ireland-based Medtronic continues to lead the charge toward value-based care, and it's beginning to pay off in a big way.  One of the company's value-based care partners, UnitedHealthcare, has seen a 27% decline in the rate of preventable hospital admissions for Medtronic insulin pump users compared to patients on multiple daily insulin injections, according to an analysis of more than 6,000 members with diabetes on Medtronic MiniMed 630G and previous generation insulin pumps. And that's just in the first year of the partnership. The analysis included a mix of members using both standalone insulin pumps and pumps integrated with continuous glucose monitors (CGM).   In 2016, UnitedHealthcare and Medtronic announced an expanded relationship that gave UnitedHealthcare members with diabetes access to advanced insulin pump technologies and comprehensive support services offered by Medtronic. These offerings currently include the company's most advanced MiniMed 670G hybrid closed-loop system featuring SmartGuard technology and Guardian Sensor 3 - the only system able to automate the delivery of a personalized amount of basal insulin every 5 minutes based on real-time sensor glucose values. The recently reported first-year results reported today are from the measurement period of July 2016 through June 2017 and do not include use of Medtronic's newest insulin pump, the MiniMed 670G system, which was commercially launched at the end of the measurement period. A growing ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news